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ControlAbstract Background: Hyperglycemia is common among critically ill patients and is associated
with increased morbidity and mortality and there is no clear answer to the question: which to apply
tight or conventional glycemic control?
Objective: Evaluation and comparison of the effects of tight versus conventional glycemic control
on critically ill patients in our surgical intensive care unit (ICU).
Design: Prospective randomized controlled trial.
Methods: 120 Patients were divided into two groups: group (I) received intensive insulin therapy
targeting blood glucose level between 80 and 110 mg/dl, who referred to as intensive treatment
group, and group (II) received conventional insulin therapy targeting blood glucose level between
150 and 200 mg/dl, and referred to as conventional treatment group.
Results: 120 Patients were enrolled in the study, the incidence of hypoglycemia (blood glucose
<70 mg/dl) was 29.09% in group I who received intensive insulin therapy versus 6.15% in group
II who received conventional insulin therapy (p value 0.000) with no demonstrable complications,
regarding mortality rate, impairment of Liver function tests, change in total leukocytic count, the
need for red blood cell transfusion, ICU stay and Total hospital stay and we reported no statistical
signiﬁcant difference between the two groups.
Conclusion: Tight glycemic control for critically ill patients in ICU in poor resources countries
showed increased incidence of hypoglycemia with no signiﬁcant beneﬁts when compared with
conventional glycemic control.
ª 2015 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.
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Hyperglycemia is common among critically ill patients and is
associated with increased morbidity and mortality, and in
the past decades there was strong recommendation for tight
glycemic control [1–3] as Van den Berghe et al. [4] reported a
dramatic 42% relative reduction in mortality in the surgical
Intensive Care Unit (ICU) when blood glucose was normalized
to 80–110 milligram per deciliter (mg/dl) by means of insulin
infusion in a prospective, randomized fashion. However this
strategy was associated with increased risk of hypoglycemia
[5–6]. Few years later, the same authors demonstrated no mor-
tality beneﬁt from intensive glucose control in their medical
ICU, except in a subgroup requiring critical care for 3 or more
days [7].
The Normoglycemia in Intensive Care Evaluation-Survival
Using Glucose Algorithm Regulation (NICE-SUGAR) trial
compared Intensive and conventional glycemic control in a
randomized, unblinded fashion in 6104 patients in the
ICU and demonstrated that intensive insulin therapy (target
81–108 mg/dL) in critically ill patients was associated with
increased 90-day mortality when compared with conventional
treatment (target 6180 mg/dL) [8].
So into this controversy the question was If intensive insu-
lin therapy targets blood glucose level (80–110 mg/dL) can be
proven effective in optimal conditions, how to make that ben-
eﬁt available to millions of critically ill patients in both devel-
oped and poor resources countries around the world.
There is no clear answer to the complex problem of glyce-
mic control in critically ill adults; at present, targeting tight
glycemic control cannot be said to be either right or wrong.
2. Aim of the work
Our objective was to evaluate and compare the effects of tight
glycemic versus conventional glycemic control on critically ill
patients in our surgical intensive care unit (ICU) regarding
mortality, incidence of hypoglycemia, ICU length of stay, total
hospital stay and occurrence of complications as sepsis and
organ dysfunction e.g.; acute respiratory distress syndrome
(ARDS), hemodynamic instability, renal and hepatic dysfunc-
tion and need for red cell transfusion.
3. Methods
3.1. Study population
After getting the approval from Ethics and Research Commit-
tee of Anesthesia Department, Faculty of Medicine, Cairo
University and obtaining written informed consents, all post-
operative critically ill hyperglycemic patients between 20 and
70 years admitted to surgical intensive care unit during the per-
iod 2010–2012 were included in the study excluding patients
with sepsis, hemodynamic instability, ARDS, renal dysfunc-
tion (creatinine above 2 mmol/l) and chronic hepatic
dysfunction.
3.2. Sample size calculation
We used standard methods to calculate sample sizes for a trial
with 80% power to detect a treatment effect and 95%conﬁdence level. The sample size calculated to detect a conﬁ-
dence interval of 0.5–5 in the percentage incidence of hypo-
glycemia as a complication of the glycemic control protocols
was 102. So we included 120 patients in the different study
groups.3.3. Study design
On admission to the intensive care unit, patients were ran-
domly allocated into two groups using a closed envelope group
(I) who received intensive insulin therapy to achieve blood glu-
cose level between 80 and 110 mg/dl, and referred to as inten-
sive treatment group, and the other group (II) received
conventional insulin therapy targeting blood glucose level
between 150 and 200 mg/dl and this group referred to as con-
ventional treatment group.
If patients were on insulin therapy before ICU admission so
hyperglycemic critically ill patients were classiﬁed according to
total insulin dose in the preceding 24 h before admission into
insulin-sensitive (who received <50 units insulin/day and
those patients who were not on insulin therapy), usual
(received 50–100 units insulin/day), or insulin-resistant (who
received >100 units insulin/day) categories. After enrollment,
venous blood samples were sent to the laboratory to determine
basal blood glucose level and correlate the result with that
determined with the glucometer, and this is to know the error
factor between the two results as glucometer was used during
rest of the day. Capillary blood obtained via ﬁnger stick was
checked every hour until 4 successive values within the target
range: (80–110 mg/dl) in intensive treatment group and (150–
200 mg/dl) in conventional treatment group.
Once the target range was achieved, blood glucose values
were checked every 2 h.
Management of hypoglycemia: if the blood glucose level
was less than 70 mg/dl, the insulin infusion was stopped, and
the patient was given 50 ml of 25% dextrose in water as a slow
intravenous infusion over 5 min and the blood glucose level
was checked every 15 min for 3 times.
For patients received total parenteral nutrition, insulin was
not added to their total parenteral feeding except when daily
insulin requirements exceeded 50 units, in which case two-
thirds of the previous day’s total insulin dose was added to
the next feeding.
Intensive glucose control: target blood glucose level 80–
110 mg/dl. No insulin infusion was started if the initial blood
glucose level was 110 mg/dl or less. If the initial blood glucose
level was greater than 110 mg/dl but less than 500 mg/dl, then
an insulin infusion was started at a rate (blood glucose level in
mg/dl) · 0.01 units/h. If the initial blood glucose level was
500 mg/dl or greater, then an insulin infusion was started at
6 units/h.
For blood glucose levels between 201 and 250 mg/dl, the
insulin infusion was increased by 3–4 units/h and an intra-
venous bolus of regular insulin was given 2–3 units for an insu-
lin sensitive subject, 4–5 units for a usual subject, and 6–8 units
for an insulin-resistant subject. For blood glucose levels
between 141 and 200 mg/dl, the insulin infusion was increased
by 1–2 units/h and intravenous bolus of regular insulin was
given 2 units for an insulin sensitive subject, 3 units for a
usual subject, and 6 units for an insulin resistant subject.
For blood glucose levels between 111 and 140 mg/dl the insulin
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Figure 1 Incidence of mortality in group I and group II. Causes
of mortality in group I (intensive treatment group) included sepsis,
myocardial infarction, hypovolemic shock and Central nervous
system (CNS) catastrophe with an incidence of 70%, 10%, 10%
and 10% respectively of mortality cases, while in group II
(conventional treatment group) causes of mortality included
sepsis, respiratory failure and CNS catastrophe with an incidence
of 55%, 33% and 11% respectively of mortality cases.
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glucose levels between 80 and 110 mg/dl the insulin infusion
will be continued at the same rate. For blood glucose levels
between 70 and 79 mg/dl, the insulin infusion was decreased
1–2 units/h.
For blood glucose levels less than 70 mg/dl, hypoglycemia
management was initiated as described above. When blood
glucose level exceeded 95 mg/dl, the insulin infusion was
resumed again.
Conventional glucose control: target blood glucose level
150–200 mg/dl. No insulin infusion was started if the initial
blood glucose level was 200 mg/dl or less. If the initial blood
glucose level was greater than 200 mg/dl, but less than
500 mg/dl, then an insulin infusion was started at a rate (blood
glucose level in mg/dl) · 0.01 units/h. If the initial blood glu-
cose level was greater than 500 mg/dl, then an insulin infusion
was started at 6 units/h.
For blood glucose levels between 251 and 300 mg/dl, the
insulin infusion was increased by 1–2 units/h and an intra-
venous bolus of regular insulin was given 2 units for an insulin
sensitive-subject, 3 units for a usual subject, and 6 units for an
insulin-resistant subject. For blood glucose levels between 201
and 250 mg/dl, the insulin infusion will be increased by 0.5–1
unit/h. For blood glucose levels between 150 and 200 mg/dl
the insulin infusion was continued at the same rate. For blood
glucose levels between 120 and 149 mg/dl, the insulin infusion
was decreased by 1–2 units/h. For blood glucose levels between
70 and 119 mg/dl, the insulin infusion was decreased 2–
3 units/h.
For blood glucose levels less than 70 mg/dl, hypoglycemia
management as described above will be initiated. When the
blood glucose level exceeded 190 mg/dl, the insulin infusion
was resumed again.
3.4. Monitoring and measurement
On ICU admission a complete history and physical examina-
tion were recorded for each patient enrolled in the study.
 APACHE II (‘‘Acute Physiology and Chronic Health Eval-
uation II’’) score [9] was calculated.
 Blood samples were obtained by ﬁnger lancet or from an
arterial catheter. Blood glucose level was measured at the
bed side with (One Call Plus) glucometer and (One Call
Plus) test strips.
 HbA1C (Glycosylated hemoglobin).
 Blood pressure, heart rate and central venous pressure were
monitored to assess hemodynamic stability.
 Blood gases to assess respiratory functions.
 Liver and kidney functions (ALT, AST, urea and
creatinine).
 Complete Blood Count (CBC) to assess bone marrow
function.
3.5. Data collection
Age, sex, body weight, APACHE II score, and associated
comorbidities were recorded on admission for each patient.
Blood glucose level will be recorded on admission;
subsequently, every 4 h, daily at 8 am and daily maximal andminimal blood glucose levels were determined. Mortality rate,
number of organ failure, ICU stay and total hospital stay were
recorded for every patient.
Systolic blood pressure, heart rate, central venous pressure,
hemoglobin, total leukocytic count, creatinine, Alanine
Transaminase and Aspartate Transaminase enzymes were
recorded during ﬁrst ﬁve days of starting glycemic control after
admission in ICU.3.6. Statistical analysis
Data will be analyzed using SPSS 13 program and microsoft
excel 2007. Numerical data will be presented as means, modes,
ranges of minimum and maximum as well as the standard devi-
ation of the mean from the study population. Also, ordinal
and categorical data will be presented as numbers and percent
of total. Groups will be compared using one way and two way
analysis of variance and Kruskal Wallace analysis of variance
as appropriate to the data to be analyzed.4. Results
There was no statistical signiﬁcant change between the two
groups regarding systolic blood pressure during the ﬁrst ﬁve
days of starting glycemic control.
There was no statistical signiﬁcant change in the heart rate
between the two groups during the ﬁrst ﬁve days of starting
glycemic control.
There is no statistical signiﬁcant difference in the central
venous pressure between the two groups during the ﬁrst ﬁve
days of starting glycemic control.
Patients needed inotropic support in group I represented
(14.5%) while in group II were (6.1%).
Creatinine level showed no statistical signiﬁcant change
between the two groups during the ﬁrst ﬁve days after starting
glycemic control.There was no statistical signiﬁcant difference
in hemoglobin level between the two groups during the ﬁrst
ﬁve days of starting glycemic control.
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Figure 2 Percentage of hypoglycemia in group I and group II.
Incidence of hypoglycemia was 29% in group I (intensive
treatment group), and 6% in group II (conventional treatment
group) with P value <0.05 which is statistically signiﬁcant.
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Figure 3 Percentage of respiratory failure in group I (intensive
treatment group) and Group II (conventional treatment group).
Incidence of respiratory failure in group I was 12.7% versus
10.7% in group II with P value (0.667) which is statistically
insigniﬁcant.
Table 1 Demographic data of IIT group (55 patients, group I)
and conventional group (65 patients, group II). Data are
represented as mean ± standard deviation (SD) and
percentage.
Group I Group II
Age 46.4 ± 19.03 42.17 ± 16.68 P value (0.202)
Weight in kg 76.82 ± 12.74 76 ± 12.06 P value (0.72)
Male (%) 58.18 58.46 i value (0.968)
Female (%) 41.82 41.54
Diabetic (%) 38.18 38.46 P value (0.968)
Nondiabetic
(%)
61.82 61.54
APACHE II 14.07 ± 6.51 13.31 ± 6.66 P value (0.527)
APACHE II (Acute Physiology and Chronic Health Evaluation II)
and P value <0.05 means signiﬁcant.
Table 2 Systolic blood pressure in group I (55 patients) and group II
deviation.
SBP day1 SBP day2
Group I 124.27 ± 23.2 120 ± 23.54
Group II 127.69 ± 22.81 124.79 ± 17.65
P value 0.419 0.305
Group I (intensive treatment group), Group II (conventional treatmen
signiﬁcant.
Table 3 Heart rate in group I (55 patients) and group II (65 patient
HR day1 HR day2
Group I 106.2 ± 16.43 104.24 ± 15.43
Group II 108.98 ± 19.65 103.54 ± 14.32
P value 0.4 0.831
Group I (intensive treatment group), Group II (conventional treatment g
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ference between the two groups during the ﬁrst ﬁve days after
starting glycemic control.
There was no statistical signiﬁcant difference between
group I and group II regarding ICU and total hospital stay.
14.5% of patients in group I and 9% in group II were on
steroid therapy, almost all patients of group I needed insulin
therapy while only 44.6% of group II needed insulin therapy
(see. Figs. 1–3 and Tables 1–9).
5. Discussion
The current study demonstrated that patients who received
intensive insulin therapy showed higher incidence of hypo-
glycemia and mortality rates with no obvious difference in
complications of the cardio-respiratory system, liver and
kidney functions when they were compared with conventional
glycemic control group (group II).(65 patients). Data are represented in terms of mean ± standard
SBP day3 SBP day4 SBP day5
116.56 ± 25.22 117.75 ± 24.63 121.92 ± 27.2
124.22 ± 16.27 121.5 ± 18.99 117.65 ± 18.12
0.155 0.593 0.63
t group), SBP (systolic blood pressure), and P value < 0.05 means
s). Data are represented in terms of mean ± standard deviation.
HR day3 HR day4 HR day5
103.25 ± 18 106.7 ± 17.82 108.08 ± 18.43
99.97 ± 15.42 100.9 ± 17.37 102.24 ± 17.6
0.437 0.304 0.389
roup), HR (heart rate), and P value < 0.05 means signiﬁcant.
Table 4 Central venous pressure in group I (55 patients) and group II (65 patients). Data are represented in terms of mean and
standard deviation.
CVP day1 CVP day2 CVP day3 CVP day4 CVP day5
Group I Mean ± SD 6.91 ± 4.58 8.24 ± 2.15 8.53 ± 2.53 10.7 ± 3.92 9.62 ± 3.36
Group II Mean ± SD 7.02 ± 3.84 8.38 ± 2.36 8.44 ± 2.6 8.9 ± 3.32 10 ± 2.98
P value 0.892 0.789 0.884 0.126 0.747
Group I (intensive treatment group), Group II (conventional treatment group), CVP (central venous pressure), and P value < 0.05 means
signiﬁcant.
Table 5 Creatinine in group I (55 patients) and group II (65 patients). Data are presented in terms of mean ± standard deviation.
Creat day1 Creat day2 Creat day3 Creat day4 Creat day5
Group I 1.04 ± 0.34 1.15 ± 0.58 1.14 ± 0.73 1.24 ± 0.84 1.44 ± 1.16
Group II 0.99 ± 0.31 1.17 ± 0.49 1.3 ± 1.04 1.45 ± 1.2 1.7 ± 1.6
P value 0.47 0.904 0.471 0.536 0.613
Group I (intensive treatment group), Group II (conventional treatment group), creat (Creatinine), Creatinine reference range (0.6–1.3 mmol/l)
and P value < 0.05 means signiﬁcant.
Table 6 Liver enzymes in group I (55 patients) and group II (65 patients). Data are presented in terms of mean ± standard deviation.
Day1 Day2 Day3 Day4 Day5
Group I ALT 64.18 ± 167.64 50.81 ± 100.73 36.09 ± 51.48 27.2 ± 9.98 26.23 ± 5.78
AST 69.75 ± 162.3 53.76 ± 72.9 49.47 ± 68 39.05 ± 22.51 35.08 ± 6.59
Group II ALT 54.31 ± 112.1 53.98 ± 120.1 39.25 ± 46.58 39.15 ± 33.64 33.65 ± 20.72
AST 52.48 ± 73.09 60.63 ± 117.76 53.22 ± 60.59 62.9 ± 72 60 ± 87.05
P value (ALT) 0.711 0.895 0.798 0.142 0.176
P value (AST) 0.468 0.742 0.817 0.171 0.257
Group I (intensive treatment group), Group II (conventional treatment group), (ALT) Alanine Transferase, (AST) Aspartate Transferase., ALT
reference range (30–65 mmol/l). AST reference range (15–37 mmol/l), (P value (ALT)) p value regarding Alanine Transferase between the two
groups, (P value (AST)) p value regarding Aspartate Transferase between the two groups, and P value < 0.05 means signiﬁcant.
There is no statistical signiﬁcant change in Alanine transferase and Aspartate transferase enzymes between the two groups during the ﬁrst ﬁve
days of starting glycemic control.
Table 7 Hemoglobin (Hb) in group I (55 patients) and group II (65 patients) in gm/dl. Data are presented in terms of
mean ± standard deviation.
Hb day1 Hb day2 Hb day3 Hb day4 Hb day5
Group I 10.12 ± 1.65 9.79 ± 1.63 9.6 ± 1.52 9.37 ± 1.2 8.67 ± 0.69
Group II 10.11 ± 2.27 9.52 ± 1.3 10.07 ± 1.69 9.62 ± 1.35 9.37 ± 1.18
P value 0.991 0.402 0.245 0.539 0.054
Group I (intensive treatment group), Group II (conventional treatment group), Hb (Hemoglobin), and P value < 0.05 means signiﬁcant.
Table 8 Total leukocytic count (TLC) in group I (55 patients) and group II (65 patients). Data are presented in terms of
mean ± standard deviation.
TLC day1 TLC day2 TLC day3 TLC day4 TLC day5
Group I 11320 ± 4800 11965 ± 4177 12625 ± 6163 12060 ± 5671 14125 ± 8259
Group II 12757 ± 9253 13746 ± 6193 12268 ± 5187 15094 ± 7061 15971 ± 6836
P value 0.278 0.118 0.803 0.149 0.551
Group I (intensive treatment group), Group II (conventional treatment group), TLC (total leukocytic count), P value < 0.05 means signiﬁcant.
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Table 9 ICU and total hospital stay in group I (55 patients)
and group II (65 patients) in days. Data are presented in terms
of mean ± standard deviation.
Group I Group II
ICU stay 3.76 ± 4 4.15 ± 5.52 P value (0.655)
Total hospital stay 8.6 ± 4.92 9.06 ± 5.74 P value (0.636)
Group I (intensive treatment group), Group II (conventional
treatment group), (ICU) intensive care unit, and P value < 0.05
means signiﬁcant.
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<70 mg/dl) was 29.09% in group I and 6.15% in group II with
(p value 0.00) with no demonstrable complications.
These results were in line with NICE SUGAR trial which is
conducted in a randomized, unblinded fashion over 6104 ICU
patients, in 41 hospitals in Australia, New Zealand, and
Canada and at the Mayo Clinic in the United States and
reported that 6.8% of patients in the intensive-control
group experienced severe hypoglycemia (blood glucose level
640 mg/dl) versus 0.5% in the conventional-control group
(P< 0.001) [8].
Two multicenter studies [5,6] reported unacceptably high
rates of hypoglycemia, and one trial was prematurely termi-
nated for this reason [6].
The higher incidence of hypoglycemia in our study may be
due to the higher reference value (70 mg/dl) than that is con-
sidered in other mentioned studies and also decreased ratio
of nurses per ICU bed.
Our study reported insigniﬁcant increase in mortality rates
in group I (18.18%) versus (13.85%) in group II, with a P
value 0.40.
NICE SUGAR study reported that the total mortality in
the intensive-control group was (27.5%) and in the
conventional-control group was (24.9%) with P value 0.02 [8].
The difference of Values of mortality rates may be due the
long term follow-up of patients (90 days) in NICE SUGAR
study, while it is limited to the period of hospital stay in the
current study.
On the contrary Van den Berghe et al. [4] conducted a study
on postoperative mechanically ventilated patients after cardiac
surgery, with a total number of 1548 patients enrolled and
reported 4.6% mortality rate in intensive treatment group, as
compared with 8.0% in the conventional-treatment group, rep-
resenting an apparent risk reduction of 42% (95% conﬁdence
interval, 22–62%). This may be due to the quality of patients
and the special type of care that those patients may be
received.
In the current study 14.5% patients of group I versus
6.1% in group II needed inotropic or vasopressor support
and there was insigniﬁcant difference between the two
groups regarding systolic blood pressure and the percentage
of patients who experienced respiratory failure during
their course in ICU (12.73% in group I versus 10.77% in
group II).
On the contrary Greet Van den Berghe et al. demonstrated
that 75% of patients on tight glycemic control needed inotro-
pic or vasopressor support versus 74.8% in the conventional
treatment group.Regarding respiratory complications Van den Berghe et al.
compared duration of mechanical ventilation between the two
groups and reported that there was statistical signiﬁcant
decrease in number of patients on tight glycemic control, while
in the NICE SUGAR study there was statistical insigniﬁcant
difference between the two groups [8].
The current study showed statistical insigniﬁcant
increase in serum creatinine between the two groups which
is in line with NICE SUGAR study that demonstrated
that there was no signiﬁcant difference between the two
treatment groups regarding renal replacement therapy
(P= 0.39).
Renda Soylemenz et al.’s meta analysis including Twenty-
nine randomized controlled trials with total number of 8432
patients, reported that Tight glucose control was not associ-
ated with signiﬁcant risk reduction for new need for dialysis
(11.2% versus 12.1% in IIT and conventional groups respec-
tively) [10].
In contrast to our study, Van den Berghe et al. reported
that 12.3% of the conventional control group showed statisti-
cal signiﬁcant increase in creatinine level (creatinine
>2.5 mg/dl) versus 9% in IIT group.
Regarding impairment of Liver function tests, change in
total leukocytic count, the need for red blood cell transfusion,
ICU stay and Total hospital stay we reported no statistical
signiﬁcant difference between the two groups; however, Greet
Van Den Berghe et al. reported that patients who experienced
deterioration in liver functions in IIT group represented
22.4% versus 26.7% in conventional group with P value
0.04, and reported that incidence of septicemia in IIT
group was 4.2% while in conventional group was 7.8% with
P value 0.003 [4].
However Renda Soylemenz et al.’s meta analysis reported
signiﬁcantly decreased risk of septicemia (10.9% versus
13.4% in IIT and conventional groups respectively) [10].
The NICE SUGAR study and Van den Berghe et al.
reported no statistical signiﬁcant difference regarding ICU stay
and Total hospital stay between the two groups [8].
In this study 100% of patients of group I needed insulin
therapy while only 44.6% of group II needed insulin therapy.
Van den Berghe et al., reported that all patients of intensive
insulin group were treated with insulin and only 39% of the
patients treated with the conventional approach received insu-
lin [4].
In the NICE-SUGAR trial, 69% of subjects in the
conventional treatment group received insulin and, 97%
of subjects in the intensive treatment group received
insulin [8].6. Limitations
Nurse to patient ratio was 2:1 in most cases but sometimes was
3:1 so it was mandatory to omit these patients from intensive
treatment group to avoid higher incidence of hypoglycemia
(5 patients).
Length of stay in ICU is higher than the expected values
due to the delay in discharge in some cases because of the
miscommunication between ICU and wards.
We have no speciﬁc isolation system in our ICU, so the
incidence of infection was higher than expected.
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Tight glycemic control for critically ill patients in ICU in poor
resources countries showed increased incidence of mortality
and hypoglycemia with no signiﬁcant beneﬁt when compared
with conventional glycemic control.
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